MedPath

Boehringer Ingelheim USA Corporation

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 1015550
Drug: BI 101550
Drug: Placebo
First Posted Date
2012-05-09
Last Posted Date
2015-12-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
70
Registration Number
NCT01594515
Locations
πŸ‡©πŸ‡ͺ

1305.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Phase 1
Completed
Conditions
Carcinoma, Hepatocellular
Interventions
First Posted Date
2012-05-08
Last Posted Date
2016-02-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT01594125
Locations
πŸ‡―πŸ‡΅

1199.120.001 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo, Japan

πŸ‡―πŸ‡΅

1199.120.005 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan

πŸ‡―πŸ‡΅

1199.120.003 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan

and more 2 locations

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 163538 XX

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo to BI 163538 XX
Drug: BI 163538 XX
First Posted Date
2012-04-30
Last Posted Date
2013-10-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT01587391
Locations
πŸ‡©πŸ‡ͺ

1291.1.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 187004 CL
Drug: Placebo to BI 187004 CL
First Posted Date
2012-04-30
Last Posted Date
2013-11-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
72
Registration Number
NCT01587417
Locations
πŸ‡©πŸ‡ͺ

1307.1.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Linagliptin/metformin
Drug: Metformin
Drug: Linagliptin
First Posted Date
2012-04-20
Last Posted Date
2013-08-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT01581931
Locations
πŸ‡©πŸ‡ͺ

1288.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2012-04-20
Last Posted Date
2017-08-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT01581658
Locations
πŸ‡―πŸ‡΅

1245.53.001 Boehringer Ingelheim Investigational Site, Kurume, Fukuoka, Japan

Safety Tolerability and Pharmacokinetic of BI 411034

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 411034
Drug: Placebo
First Posted Date
2012-04-20
Last Posted Date
2017-08-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
62
Registration Number
NCT01581684
Locations
πŸ‡©πŸ‡ͺ

1308.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

Phase 1
Completed
Conditions
Hepatitis C
Interventions
Drug: BI 201335
First Posted Date
2012-04-19
Last Posted Date
2015-07-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT01580306
Locations
πŸ‡©πŸ‡ͺ

1220.58.1 Boehringer Ingelheim Investigational Site, Kiel, Germany

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Phase 3
Completed
Conditions
Hepatitis C
Interventions
Drug: BI 201335 high dose
Drug: BI 201335 low dose
First Posted Date
2012-04-18
Last Posted Date
2015-08-03
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
131
Registration Number
NCT01579474
Locations
πŸ‡―πŸ‡΅

1220.54.08115 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan

πŸ‡―πŸ‡΅

1220.54.08101 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan

πŸ‡―πŸ‡΅

1220.54.08104 Boehringer Ingelheim Investigational Site, Chuo-ku, Chiba, Japan

and more 21 locations

Drug-drug Interaction of BI 201335 and Microgynon

Phase 1
Completed
Conditions
Hepatitis C, Chronic
Interventions
First Posted Date
2012-04-04
Last Posted Date
2015-08-03
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT01570244
Locations
πŸ‡©πŸ‡ͺ

1220.56.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Β© Copyright 2025. All Rights Reserved by MedPath